Early cancer detection is a key determinant of patient outcomes. Liquid biopsy is a sensitive diagnostic technology that uses peripheral blood to detect biomarkers for solid and liquid tumors. Current technologies detect circulating tumor cells and tumor DNA, but lack the sensitivity to identify cancer biomarkers from proteins present in the circulation. In this webinar, Klaus Pantel and Christoffer Gebhardt will discuss recent advances in liquid biopsy technology that allow researchers to detect protein biomarkers for diverse cancer types, including metastatic melanoma.
Topics to be covered
Speaker Information:
Klaus Pantel, MD
Chairman and Founding Director, Institute for Tumor Biology
Executive Board Member, University Cancer Center Hamburg (UCCH)
University Medical Center Hamburg-Eppendorf (UKE)
Hamburg, Germany
Visiting Professor, University of Bergen, Norway
Christoffer Gebhardt, MD
Head, University Skin Cancer Center Hamburg
Vice Chairman, Department of Dermatology and Venereology
University Medical Center Hamburg-Eppendorf (UKE)
Hamburg, Germany
Drug Discovery News
1000 N West Street | Wilmington | Delaware | 19801 | US
Email: privacy@drugdiscoverynews.com
© 2021 Old River Publications LLC. All rights reserved
Drug Discovery News needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy